Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Mirum Pharmaceuticals, Inc.
Study will consist of 3 study arms. Approximately 150 participants will be randomized 2:2:1 to one of the following treatment arms:
* Arm 1: Participants randomized to Arm 1 will receive brelovitug 300 mg subcutaneously once weekly.
* Arm 2: Participants randomized to Arm 2 will receive brelovitug 900 mg subcutaneously once every 4 weeks.
* Arm 3: Participants randomized to Arm 3 will attend study clinic visits and delay treatment with brelovitug. At Week 24, all participants will receive brelovitug 300 mg subcutaneously once weekly.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Willing and able to provide written informed consent.
Chronic HDV infection
HDV RNA \>500 IU/mL at Screening.
Abnormal ALT (\>upper limit of normal) at Screening.
Willing to take or already taking HBV nucleos(t)ide therapy
You may not be if
Pregnant or nursing females.
Unwilling to comply with contraception requirements during the study.
Difficulty with blood collection and/or poor venous access for the purposes of phlebotomy
Presence of other liver disease(s) (does not include HBV or HDV infection) such as non-alcoholic steatohepatitis (NASH), alcohol associated hepatitis, cholestatic liver disease, hepatocellular carcinoma.
